NIKKEI 225
38,299.71 +25.66 (+0.07%) HANG SENG
18,163.11 +400.08 (+2.25%) CRUDE OIL
79.46 +0.46 (+0.58%) GOLD FUTURES
2,329.00 +18.00 (+0.78%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,875.96 -2,026.06 (-4.23%)
Biophytis S.A. (0D1W.L)
| Previous close | 0.0023 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 153,519 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2640 |
| Earnings date | 08 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
BenzingaWhy Is Penny Stock Biophytis Trading Higher On Tuesday?
Monday, Biophytis SA (NASDAQ:BPTS) announced the launch of a new clinical development program named OBA, with BIO101 (20-hydroxyecdysone) as a potential treatment for obesity combined with GLP-1 receptor agonists. The OBA Phase 2 clinical study is expected to start in mid-2024, upon regulatory approvals, with the first patients expected to be treated in the second half of 2024. BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs and following hypocaloric dietin
ZacksBiophytis (BPTS) to Begin Phase II Obesity Study, Stock Up
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.
Insider Monkey40 Cities with the Lowest Life Expectancy in the US
In this article, we look at 40 cities with the lowest life expectancy in the US. You can skip our section on developments in the pharmaceutical and biotech industries to enhance longevity and head over directly to 10 Cities with the Lowest Life Expectancy in the US. Average lifespan in the US climbed from just […]
